Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Melanoma 56Carcinoma, Non-Small-Cell Lung 56Carcinoma, Renal Cell 34Neoplasms 33Neoplasm Metastasis 29Colorectal Neoplasms 23Squamous Cell Carcinoma of Head and Neck 22Pancreatic Neoplasms 22Carcinoma, Hepatocellular 21Carcinoma, Transitional Cell 18Lung Neoplasms 17Glioblastoma 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 13Breast Neoplasms 13Urinary Bladder Neoplasms 11Stomach Neoplasms 11Head and Neck Neoplasms 10Uveal Melanoma 9Recurrence 8Myelodysplastic Syndromes 8Lymphoma 8Leukemia, Myeloid, Acute 8Advanced Cancer 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Kidney Neoplasms 7Hodgkin Disease 7Hematologic Neoplasms 7Glioma 7

Interventions

lutetium Lu 177 dotatate 2gallium Ga 68 dotatate 2Magnetic Resonance Spectroscopy 2Ga(III)-DOTATOC 2lanreotide 1copper dotatate CU-64 1amino-acid, glucose, and electrolyte solution 1X-Rays 1Radiosurgery 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1E-7386 1Disulfides 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastro-enteropancreatic neuroendocrine tumor × Nivolumab × Clear all
NCT05262556 2025-08-07

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡